{"analyses":[{"ciLowerLimit":"3.29","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"23.64","groupDescription":"OS Rate at 1 year","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0095","paramType":"Difference in Event Free Rate","paramValue":"13.46","statisticalMethod":"Z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.23"},{"groupId":"OG001","value":"51.69"}]}],"title":"1 Year"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","value":"NA"},{"comment":"Insufficient number of participants with events.","groupId":"OG001","value":"NA"}]}],"title":"2 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"OS rates at 1 and 2 years is defined as the proportion of participants who are alive 1 year and 2 years after randomization, respectively.","groups":[{"description":"Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m\\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG000","title":"Placebo + Carboplatin + Etoposide"},{"description":"Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG001","title":"Atezolizumab + Carboplatin + Etoposide"}],"paramType":"NUMBER","populationDescription":"The ITT population was defined as all randomized participants, regardless of whether the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"1 year, 2 years","title":"OS Rate at 1 Year and 2 Years in the Global Population","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}